SciELO - Scientific Electronic Library Online

 
vol.31 número3Comparación del Hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de MéxicoTécnicas moleculares para la detección e identificación de patógenos en alimentos: ventajas y limitaciones índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Peruana de Medicina Experimental y Salud Publica

versão impressa ISSN 1726-4634

Resumo

VIRU-LOZA, Manuel A  e  PALACIOS-GUILLEN, Alaciel Melissa. Hyperuricemia and progression of chronic cardiorenal compromise. Rev. perú. med. exp. salud publica [online]. 2014, vol.31, n.3, pp.530-534. ISSN 1726-4634.

In order to determine whether hyperuricemia is associated with the progression of chronic cardiorenal compromise (CCC), a retrospective cohort study was performed which included 103 patients in whom CCC was defined as the simultaneous presence of chronic kidney disease (CKD) and chronic heart disease (CHD). CKD progression was defined as a 50% reduction of glomerular filtration rate estimated by the MDRD-4 equation. Hyperuricemia was defined as basal levels of uric acid ≥ 7 mg/dL. None of the studied variables showed association with the progression of CCC or CHD. Independent predictors of CKD progression were basal hyperuricemia (HR 4.41, 95% CI: 1.02-18.94) and SAP in followup (HR 1.05, 95% CI: 1.01-1.09). We conclude that hyperuricemia is an independent risk factor for the progression of CKD in patients with CCC.

Palavras-chave : Uric acid; Hyperuricemia; Renal insufficiency, chronic; Cardio-renal syndrome; Arterial pressure; Follow-up studies; Disease progression.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons